VTRS · 8-K · 20261105PR000053

Acquisition / Partnership / Divestiture

Viatris Inc · 2026-11-05 · Importance 65 · Surprise 60 · In source text

Viatris agreed to acquire all outstanding common shares of Pacira BioSciences for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion. The transaction was expected to close by the end of November 2026. Viatris said the planned acquisition was excluded from its 2026 financial guidance, and management expected minimal impact on gross leverage upon closing.

Key facts

• Viatris agreed to acquire all outstanding Pacira BioSciences common shares for $36.50 per share in cash, representing aggregate equity value of $1.65 billion; the transaction was expected to close by the end of November 2026. source
• Viatris expected the Pacira transaction to have minimal impact on its gross leverage ratio upon expected closing by the end of November. source
• Viatris Inc's reconciliation lists loss on divestitures of businesses as 21.9, 13.9, —, and —. source

Impact estimates